Clinical Trial Update: Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT [Phase 1]

View source ↗

Summary

Phase 1 safety trial of a natural killer donor lymphocyte infusion from a 6/6 HLA-matched family member after nonmyeloablative autologous stem cell transplant i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Natural killer donor lymphocyte infusion (donor lymphocyte infusion enriched for natural killer cells)

Snippet

Sponsor: David Rizzieri, MD | Conditions: Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2014-06-02